Generic Name: nilutamide

Pronunciation: N/A

Abbreviation: N/A

Other Market Name: N/A

Drug Class: Hormone Therapy Medications

Company: Sanofi

Approval Status: Approved

Generic Version Available: Yes

Experimental Code: N/A

Drug Indication

Nilandron is an anti-androgen drug used to treat men with metastatic prostate cancer after surgical castration, or removal of the testicles.

General Info

Testosterone and other male hormones (androgens) stimulate prostate cancer growth. Surgical or chemical castration reduces testosterone levels, but other cells in the body can still make androgens. Drugs like Nilandron interfere with the action of androgens and decrease cancer cell proliferation.

Dosage

Dosing Info:

Nilandron is taken as a pill. The usual dose is two tablets once daily for a month, following by one tablet once daily.

Side Effects

Common side effects include pain, weakness, nausea, constipation, hot flashes, dizziness and abnormal vision. Drugs that lower androgen levels may lead to reduced sexual desire, erectile dysfunction, shrinkage of the testicles and breast pain and enlargement (gynecomastia). Potential serious side effects include liver toxicity and lung inflammation.

For More Info: http://products.sanofi.us/nilandron/nilandron.html

Co-Pay Program Info: http://products.sanofi.us/nilandron/nilandron.html

Patient Assistance Program Info: http://products.sanofi.us/nilandron/nilandron.html

Last Reviewed: September 19, 2018